Coherus crashes after FDA rejection, but Wall Street says problems manageable
June 12, 2017 at 18:19 PM EDT
Biosimilar researcher Coherus Biosciences announced that the FDA rejected its current application for CHS-1701, which aims to mimic Amgen's Neulasta.
